This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

An Approach to Management

Robert S. Rosenson, MD

Arch Intern Med. 1993;153(13):1528-1538.

Abstract
Clinical management of dyslipidemias has focused primarily on the low-density lipoprotein cholesterol (LDL-C) fraction; however, lipid disorders accompanied by low levels of high-density lipoprotein cholesterol (HDL-C) (hypoalphalipoproteinemia) are common, particularly among subjects with the diagnosis of coronary artery disease prior to age 55 years. The therapeutic objectives for high-risk subjects with dyslipidemias is directed initially toward reduction of the LDL-C fraction; thereafter, aggressive efforts aimed at raising the HDL-C fraction may be warranted. Strategies for raising the HDL-C fraction start with hygienic measures that include aerobic exercise, weight loss, smoking cessation, withdrawal of agents secondarily lowering HDL-C, and estrogen replacement. Pharmacotherapy selected according to the dyslipidemia that accompanies the HDL-C disorder is indicated for subjects who manifest premature coronary artery disease or who have a familial history of coronary artery disease and hypoalphalipoproteinemia.

(Arch Intern Med. 1993;153:1528-1538)

Author Affiliations
From the Preventive Cardiology Center, Section of Cardiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease : A Working Group Report
Gotto
Circulation 2001;103:2213-2218.
FULL TEXT  

Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study
Zema
J Am Coll Cardiol 2000;35:640-646.
ABSTRACT | FULL TEXT  

New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol
Harper and Jacobson
Arch Intern Med 1999;159:1049-1057.
ABSTRACT | FULL TEXT  

Beyond Low-Density Lipoprotein Cholesterol: A Perspective on Low High-Density Lipoprotein Disorders and Lp(a) Lipoprotein Excess
Rosenson
Arch Intern Med 1996;156:1278-1284.
ABSTRACT